ANGIOSOMA OTC Markets

Equities

SOAN

US03476L1026

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 18:00:00 2024-02-04 EST			5-day change	1st Jan Change
0.0009 ^USD	-.--%		+20.00%	-.--%

06-28	GlobeStar Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
03-12	GlobeStar Therapeutics Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Angiosoma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2020

January 28, 2021 at 02:18 pm

AngioSoma, Inc. announced earnings results for the first quarter ended December 31, 2020. For the first quarter, the company announced sales was USD 0 compared to USD 77 a year ago. Operating loss was USD 60,353 compared to USD 74,233 a year ago. Net loss was USD 124,395 compared to USD 161,037 a year ago.

Latest news about ANGIOSOMA

GlobeStar Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	06-28	CI
GlobeStar Therapeutics Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	03-12	CI
Globestar Therapeutics Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-23	CI

Chart ANGIOSOMA

Duration

Period

More charts

Company Profile

GlobeStar Therapeutics Corporation (GlobeStar Therapeutics) is a clinical-stage pharmaceutical company. The Company is focused on introducing a patented formulation of drugs for the treatment of Multiple Sclerosis and other neurodegenerative diseases. The Company owns the global license from the inventors, who are based in Italy. The Company has acquired a license for a patented method of treating neurodegenerative diseases such as Multiple Sclerosis by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration and treating neurodegeneration. GlobeStar Therapeutics is initiating discussions with the Food and Drug Administration (FDA) on clinical trial design in preparation for FDA submission and approval pathway.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research